Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Tarsus Pharmaceuticals (TARS)
Analysts from Barclays and J.P. Morgan maintained Buy ratings on Merck (MRK), Tarsus Pharmaceuticals (TARS), and Ascendis Pharma (ASND). MRK has a $150 PT from Barclays, $180 from Scotiabank. TARS has a $110 PT from Barclays, $116 from Goldman Sachs. ASND has a $318.31 avg PT. All stocks have upside potential according to analysts.
How this was made
The 30-second read
Why it matters
The consensus upgrades provide fresh bullish signals, but the impact may be modest without accompanying earnings or product news.
Market read
Analyst upgrades may prompt short‑term buying interest in the three stocks.
What to watch
Potential regulatory or clinical trial setbacks could temper the upside.
Background
Analyst rating updates and price target revisions for three healthcare companies were published on October 9‑10.
Ticker impact
Barclays and Scotiabank analysts maintained Buy ratings and raised price targets for Merck, indicating fresh bullish sentiment.
likely upward pressure as investors price in the new targets
Multiple analysts increased targets to $150 and $180, implying a 12‑13% upside from current price.
Barclays and Goldman Sachs analysts reiterated Buy ratings and lifted price targets for Tarsus Pharmaceuticals.
likely upward pressure as the market absorbs the higher targets
Target range of $101‑$116 implies ~40% upside from the last close, attracting interest.
J.P. Morgan and Cantor Fitzgerald analysts reiterated Buy ratings and set higher price targets for Ascendis Pharma.
potential upward move as investors consider the $300‑$318 target range
Consensus target indicates ~40% upside from current price, supporting a bullish view.
Market effects
The upgrades may lift sentiment across the broader healthcare sector.
U.S. healthcare stocks could see modest gains in the near term.
Limited to investors focused on U.S. biotech and pharma equities.
Counterpoint
Some investors may view the high price targets as overly optimistic given recent sector volatility.
Key entities
- Analyst FirmBarclays
Provided Buy rating and $150 target for MRK.
- Analyst FirmGoldman Sachs
Resumed coverage with Buy rating and $116 target for TARS.
- Analyst FirmJ.P. Morgan
Reiterated Buy rating for ASND.
